文献速递骨软组织肉瘤与黑色素瘤

肿瘤内免疫治疗在肿瘤学中的现状与展望

Intratumoural immunotherapies in oncology.
PubMed 文献 · Eur J Cancer · 2020-01-18

本文综述肿瘤内注射免疫治疗的现状。多数患者对免疫检查点抑制剂无持久获益,常因缺乏T细胞炎症型肿瘤微环境(TME)。瘤内治疗可将「冷」肿瘤转为「热」肿瘤,包括化学消融、溶瘤病毒、细胞因子及靶向先天免疫的Toll样受体激动剂、干扰素基因刺激因子激动剂等。黑色素瘤因免疫原性较强、皮肤转移灶易注射而领先发展,内镜与介入放射技术使内脏病灶注射成为可能。

要点

  • 瘤内治疗旨在诱导T细胞炎症,将「冷」TME转为「热」TME
  • 在研手段包括化学消融、溶瘤病毒、细胞因子及先天免疫激动剂
  • 黑色素瘤引领瘤内药物开发,正向其他瘤种及内脏病灶拓展

核心结论

  • 瘤内免疫治疗是诱导T细胞炎症、改善免疫检查点抑制剂获益人群的潜在策略,目前多类手段处于临床开发阶段。

研究设计与样本

  • 本文为综述,概述肿瘤内治疗在肿瘤学中的现状,并讨论治疗定位与合适试验设计的未来方向。

主要发现

  • 多数肿瘤患者对免疫检查点抑制剂缺乏持久获益,常与缺乏T细胞炎症型TME相关。
  • 黑色素瘤因相对免疫原性及皮肤转移灶易注射而在瘤内药物开发中领先。
  • 内镜与介入放射技术进步使瘤内药物可注射至内脏病灶。

临床怎么用

  • 对缺乏T细胞炎症的「冷」肿瘤,可考虑瘤内治疗作为诱导炎症、增敏免疫治疗的策略。
  • 瘤内治疗正从黑色素瘤扩展至其他瘤种,内脏病灶可借助内镜或介入放射技术注射。

局限性

  • 本文为综述,未报告具体研究样本量、疗效数值或统计学结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although immune checkpoint inhibitors have become the standard of care for many tumours, the majority of patients fail to achieve sustained benefit, often owing to the lack of a T-cell inflamed tumour microenvironment (TME). Directly injected intratumoural therapies present a potential strategy to induce T-cell inflammation and convert a 'cold' immune-inert TME into a 'hot' immune-inflamed TME. Various approaches including chemoablation, oncolytic viral therapy, cytokines and agents targeting innate immunity such as Toll-like receptor agonists and stimulator of interferon genes agonists are in clinical development. Thus far, melanoma has led the way in intratumoural drug development owing to its relative immunogenicity and propensity for cutaneous metastasis easily amenable to injections. However, intratumoural therapies are moving to other tumour types and advances in endoscopic and interventional radiological techniques are allowing these agents to be injected into visceral lesions. This review provides an overview of the current status of intratumoural therapies in oncology, as well as future directions regarding therapeutic niches and appropriate trial design for intratumoural agents.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Xu W, Atkinson VG, Menzies AM, et al. Intratumoural immunotherapies in oncology. Eur J Cancer. 2020. PMID: 31962197. doi:10.1016/j.ejca.2019.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。